EP 41: Mallory Abbott on Ebstein’s Anomaly, Self-Care & the Power of Gratitude
Mallory was not prepared when she underwent her first heart surgery in seventh grade: She was hoping to regain her stamina, instead she experienced what she describes as a loss of self. Mallory was born with a rare heart disease called a Ebstein’s anomaly.
In this powerful episode, Mallory Abbott recounts how she learnt to draw strength from her condition: She talks candidly about the realities of going into heart failure at age 25 and the moment when she decided to embrace herself. Ankur asks Mallory about her treatment path and her everyday experiences. They discuss the importance of having a routine and putting self-care first. Mallory shares her thoughts on social media as an asset for patient empowerment.
What does a day look like in Mallory Abbott’s life? How did she reframe her approach to her condition? What is the importance of routine? What is Mallory’s message for anyone living with a health condition?
Questions and comments can be sent to “podcast@radciffe-group.com” and may be answered by Ankur in the next episode. Guest @MazzyMystical, hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Read MoreRead Less
Brought to you by Edwards: www.edwardstavr.com
Read MoreRead Less
In one of her many posts on Instagram, we can see Dr Hafiza Khan holding a table summarising her reactogenicity after her second COVID shot. In the frame next to her is her son listing his own reactions. In this episode, Ankur asks Hafiza to talk about Instagram and reaching millennial and gen Z audiences, as well as the importance of developing and maintaining trust between different communities at a time of information overload.
Read More
All Episodes
Listen to our first episode with two guests! Ankur spoke with Emmanouil S Brilakis, MD and Michael Megaly, MD from the Minneapolis Heart Institute, Abbott Northwestern Hospital about their article on the role of drug-coated balloons in small-vessel coronary artery disease (SVD) published in US Cardiology Review 13.1. Percutaneous coronary intervention of SVD remains challenging due to difficulties with device delivery and high restenosis rate, making drug-coated balloons an attractive emerging option in patients with SVD.
In this brilliant conversation, Ankur, Emmanouil and Michael unravel the potential advantages, challenges and practical realities of using drug-coated balloons in SVD, and the findings of the latest randomised controlled trials studying this area.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology. [Disclaimer: The use of drug-coated balloons in coronay intervention is still off-label; it has not been approved by the FDA.]
Read More
In this brilliant conversation, Ankur, Emmanouil and Michael unravel the potential advantages, challenges and practical realities of using drug-coated balloons in SVD, and the findings of the latest randomised controlled trials studying this area.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology. [Disclaimer: The use of drug-coated balloons in coronay intervention is still off-label; it has not been approved by the FDA.]
We have observed a lot of developments in percutaneous coronary intervention (PCI) over the past 12 months with the publication of various studies and trials. This week, Ankur spoke with J. Dawn Abbott, MD, Associate Professor of Cardiology at Warren Medical School of Brown University about her recently published US Cardiology Review 13.1 article on the significant developments in PCI over the past 12 months.
Dawn is an associate editor of the journal Circulation: Cardiovascular Interventions and is widely known for her research program on PCI and peripheral arterial disease (PAD). Ankur and J. Dawn discuss multiple trials/studies that were published in 2018, including ORBITA, PIONEER-II and ABSORB. J. Dawn also shares her thoughts on the latest stent technologies.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Read More
Dawn is an associate editor of the journal Circulation: Cardiovascular Interventions and is widely known for her research program on PCI and peripheral arterial disease (PAD). Ankur and J. Dawn discuss multiple trials/studies that were published in 2018, including ORBITA, PIONEER-II and ABSORB. J. Dawn also shares her thoughts on the latest stent technologies.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
This week’s podcast guest needs no introduction! Prof Athena Poppas is one of the most widely known cardiologists in the US and current Vice-President of the American College of Cardiology! Ankur spoke to Athena about her recently published US Cardiology Review 13.1 article on whether early management of hypertension by GPs can improve outcomes.
They discuss the importance of preventative medicine, their experience of reducing hypertension with non-pharmaceutical and pharmaceutical methods, and the significance of the integrated “team approach” when treating comorbid conditions such as hypertension. Athena also shares her thoughts on cardiologists’ responsibility to shape their patients’ lifestyle choices.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Read More
They discuss the importance of preventative medicine, their experience of reducing hypertension with non-pharmaceutical and pharmaceutical methods, and the significance of the integrated “team approach” when treating comorbid conditions such as hypertension. Athena also shares her thoughts on cardiologists’ responsibility to shape their patients’ lifestyle choices.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Ankur is back with his second #AudioArticle! This week he spoke with Santiago Garcia from the Minneapolis Heart Institute about Santiago’s US Cardiology Review 13.1 article on the role of high-sensitivity cardiac troponin (hscTn) assays and their ability to rapidly rule in or rule out acute coronary syndrome (ACS) with improved sensitivity.
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Read More
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
In our first episode, Ankur explains his vision for and inspiration to start ‘Parallax’, and speaks with Chad Kliger from Lenox Hill Hospital in New York about conduction abnormalities after transcatheter aortic valve replacement (TAVR/TAVI), a review article published in US Cardiology Review 13.1 Ankur and Chad look at conduction abnormalities after TAVR/TAVI with a focus on basic conduction system anatomy in relation to the aortic valve, the mechanism, incidence, predisposing factors for occurrence, impact on mortality and finally, proposed treatment algorithms for management. Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Read More
In the second ESC 2021 episode of Parallax, Dr Ankur Kalra’s guest is Dr. Mirvat Alasnag, interventional Cardiologist and Director of Catheterization Laboratory at the King Fahad Armed Forces Hospital (KFAFH) in Saudi Arabia. Dr Alasnag was a programme committee member at this year’s ESC and regional PI of one of the late-breaking trials presented.
Read More
In this special ESC 2021 edition of Parallax, Ankur asks Purvi to review the highlights of the congress. Purvi summarises the design and findings of the trials and their importance in the treatment of patients. Ankur and Purvi discuss how the novel data presented at ESC will inform their practice.
Read More
Dr Ankur Kalra’s guest is Dr Nasrien Ezzeldin Ibrahim, Director of Heart Failure Clinical Research at Inova Heart and Vascular Institute and the writer of SPARKPLUG: The Roadmap to Confidently Ignite and Navigate Your Career Without Compromising Your Dreams.
In this candid episode of Parallax, Nasrien and Ankur open up about their experiences of being an immigrant. Ankur asks Nasrien about her journey to medicine. Nasrien shares the lessons she took away from her years under the mentorship of Dr JoAnn Lindenfeld and later, Dr. James Januzzi. Finally, Nasrien shares her recent experience of writing Sparkplug and how she embraced life with its imperfections and found her purpose.
Read More
In this candid episode of Parallax, Nasrien and Ankur open up about their experiences of being an immigrant. Ankur asks Nasrien about her journey to medicine. Nasrien shares the lessons she took away from her years under the mentorship of Dr JoAnn Lindenfeld and later, Dr. James Januzzi. Finally, Nasrien shares her recent experience of writing Sparkplug and how she embraced life with its imperfections and found her purpose.
This week’s episode starts a series in collaboration with the Heart Failure Society of America (HFSA). Host, Ankur Kalra’s guests are Robert Mentz and Anuradha Lala Senior Editorial Team of the Journal of Cardiac Failure (JCF), the official journal of the HFSA and the Japanese Heart Failure Society (JHFS).
In this practical and insightful episode, Dr Kalra asks what does diversity, equity, inclusion and belonging mean to the editorial board of JCF and what were the steps taken to put these principles into practice.
Read More
In this practical and insightful episode, Dr Kalra asks what does diversity, equity, inclusion and belonging mean to the editorial board of JCF and what were the steps taken to put these principles into practice.
This week, Dr. Ankur Kalra’s guest is Dr. Sameer Bansilal, Executive Director of U.S Medical Affairs of Cardiovascular and Renal at Bayer Pharmaceutical.
Dr. Bansilal was an Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai when he decided to seek an alternative pathway to make an impact on patients’ lives.
Read More
Dr. Bansilal was an Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai when he decided to seek an alternative pathway to make an impact on patients’ lives.